

Konstadinos G Boboridis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2619939/publications.pdf>

Version: 2024-02-01

74
papers

5,388
citations

201658
27
h-index

106340
65
g-index

77
all docs

77
docs citations

77
times ranked

3296
citing authors

#	ARTICLE	IF	CITATIONS
1	Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview. <i>Advances in Therapy</i> , 2022, 39, 5-32.	2.9	1
2	The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 453-466.	2.4	16
3	Letter to the editor: "topical preservative-free ophthalmic treatments an unmet clinical need"™. <i>Expert Opinion on Drug Delivery</i> , 2021, 18, 527-529.	5.0	2
4	Hypopyon after Primary Cryopreserved Amniotic Membrane Transplantation for Sterile Corneal Ulceration: A Case Report and Review of the Literature. <i>Case Reports in Ophthalmological Medicine</i> , 2021, 2021, 1-5.	0.5	1
5	Revisiting Ocular Allergy: Evaluating Symptoms, Benzalkonium Chloride and Efficacy of Topical Ketotifen 0.025%. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 188-190.	1.8	6
6	Response to Comments on Randomized Controlled Trial Comparing Everting Sutures with a Lateral Tarsal Strip for Involutional Lower Eyelid Entropion. <i>Ophthalmology and Therapy</i> , 2020, 9, 369-370.	2.3	0
7	Randomized Controlled Trial Comparing Everting Sutures with a Lateral Tarsal Strip for Involutional Lower Eyelid Entropion. <i>Ophthalmology and Therapy</i> , 2019, 8, 397-406.	2.3	11
8	Lack of Association of the rs11655081 ARSG Gene with Blepharospasm. <i>Journal of Molecular Neuroscience</i> , 2019, 67, 472-476.	2.3	16
9	Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre. <i>European Journal of Dermatology</i> , 2019, 29, 490-499.	0.6	16
10	Role of corneal nerves in ocular surface homeostasis and disease. <i>Acta Ophthalmologica</i> , 2019, 97, 137-145.	1.1	125
11	BDNF rs6265 (Val66Met) Polymorphism as a Risk Factor for Blepharospasm. <i>NeuroMolecular Medicine</i> , 2019, 21, 68-74.	3.4	28
12	Controlled Adverse Environment Chambers in Dry Eye Research. <i>Current Eye Research</i> , 2018, 43, 445-450.	1.5	20
13	Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages. <i>Drugs</i> , 2018, 78, 39-64.	10.9	43
14	Evaluating the novel application of cyclosporine 0.1% in ocular surface disease. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1027-1039.	1.8	29
15	Enduring remission of active and sight-threatening Graves'™ orbitopathy with rituximab: report of two cases. <i>Endocrine Journal</i> , 2018, 65, 963-967.	1.6	2
16	Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting. <i>Ocular Surface</i> , 2017, 15, 179-192.	4.4	107
17	Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves'™ orbitopathy?. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 547-553.	3.3	57
18	24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy. <i>Advances in Therapy</i> , 2017, 34, 221-235.	2.9	25

#	ARTICLE	IF	CITATIONS
19	Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting. Ocular Surface, 2017, 15, 169-178.	4.4	57
20	Graves's orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. Orphanet Journal of Rare Diseases, 2017, 12, 72.	2.7	113
21	Natural course of mild Graves' orbitopathy: is it a chronic remitting or a transient disease?. Journal of Endocrinological Investigation, 2017, 40, 257-261.	3.3	17
22	The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. European Thyroid Journal, 2016, 5, 9-26.	2.4	738
23	Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. British Journal of Ophthalmology, 2016, 100, 300-306.	3.9	332
24	Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search. Advances in Therapy, 2015, 32, 595-611.	2.9	55
25	New Perspectives on Lamellar Keratoplasty. Advances in Therapy, 2014, 31, 494-511.	2.9	22
26	24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost. Advances in Therapy, 2014, 31, 592-603.	2.9	19
27	Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting. Ocular Surface, 2013, 11, 246-258.	4.4	359
28	B-Cell Targeted Therapy With Rituximab for Thyroid Eye Disease: Closer to the Clinic. Survey of Ophthalmology, 2013, 58, 252-265.	4.0	21
29	Corneal Transplant Infection due to <i>Alternaria alternata</i> : A Case Report. Case Reports in Ophthalmological Medicine, 2013, 2013, 1-3.	0.5	11
30	Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4454-4463.	3.6	282
31	Descemet's Stripping Endothelial Automated Keratoplasty Using Tan Endoglide Endothelium Insertion System. Transplantation Proceedings, 2012, 44, 2759-2764.	0.6	7
32	Entropion. Ophthalmology, 2011, 118, 225-226.	5.2	4
33	Selenium and the Course of Mild Graves' Orbitopathy. New England Journal of Medicine, 2011, 364, 1920-1931.	27.0	503
34	Interventions for involutional lower lid entropion. The Cochrane Library, 2011, , CD002221.	2.8	22
35	Kaposi's Sarcoma of the Bulbar Conjunctiva in an Immunocompetent Patient. Case Reports in Ophthalmology, 2011, 2, 193-197.	0.7	12
36	Surgical orbital decompression for thyroid eye disease. The Cochrane Library, 2011, , CD007630.	2.8	47

#	ARTICLE	IF	CITATIONS
37	Childhood Orbitotemporal Neurofibromatosis Masked by Congenital Glaucoma and Buphthalmos. Journal of Pediatric Ophthalmology and Strabismus, 2011, 48, e49-51.	0.7	1
38	Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clinical Endocrinology, 2010, 72, 853-855.	2.4	44
39	Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clinical and Experimental Ophthalmology, 2010, 38, 683-687.	2.6	51
40	General Management Plan. , 2010, , 88-95.		0
41	Orbital fat decompression for Graves' orbitopathy: a literature review. Pediatric Endocrinology Reviews, 2010, 7 Suppl 2, 222-6.	1.2	5
42	A modified technique of retrograde intubation dacryocystorhinostomy for proximal canalicular obstruction. Clinical Ophthalmology, 2009, 3, 681.	1.8	6
43	Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures. British Journal of Ophthalmology, 2009, 93, 1518-1523.	3.9	133
44	Does the use of trypan blue during phacoemulsification affect the intraocular pressure?. Canadian Journal of Ophthalmology, 2009, 44, 293-296.	0.7	3
45	Management of canalicular obstructions. Current Opinion in Ophthalmology, 2009, 20, 395-400.	2.9	49
46	Orbital Exenteration for Skin Malignancies: A Single-Center Experience. Skull Base, 2009, 19, .	0.4	0
47	Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy. Clinical and Experimental Ophthalmology, 2008, 36, 130-135.	2.6	20
48	Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. European Journal of Endocrinology, 2008, 158, 273-285.	3.7	611
49	O.340 Orbital exenteration for skin malignancies. A case series. Journal of Cranio-Maxillo-Facial Surgery, 2008, 36, S86.	1.7	0
50	Declaraci3n de consenso del Grupo europeo sobre la orbitopat3a de Graves (EUGOGO) sobre el tratamiento de la orbitopat3a de Graves (OG). Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2008, 55, 356.e1-356.e13.	0.8	0
51	Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy. Thyroid, 2008, 18, 333-346.	4.5	342
52	Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. British Journal of Ophthalmology, 2007, 91, 455-458.	3.9	253
53	Efficacy and Safety of Latanoprost versus Travoprost in Exfoliative Glaucoma Patients. Ophthalmology, 2007, 114, 653-657.	5.2	69
54	A questionnaire survey on the management of Graves's™ orbitopathy in Europe. European Journal of Endocrinology, 2006, 155, 207-211.	3.7	68

#	ARTICLE	IF	CITATIONS
55	Approaches for Correcting Aponeurotic Ptosis. Ophthalmology, 2006, 113, 1889-1890.	5.2	0
56	Re: "Clinical Features and Treatment of Graves Ophthalmopathy in Pediatric Patients" Ophthalmic Plastic and Reconstructive Surgery, 2006, 22, 405-406.	0.8	0
57	Viral Conjunctivitis Interfering with the Clinical Activity Score and Management of Thyroid Ophthalmopathy. Orbit, 2006, 25, 27-29.	0.8	1
58	Recent Developments in the Medical Treatment of Thyroid Eye Disease. Orbit, 2006, 25, 117-122.	0.8	5
59	Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. European Journal of Endocrinology, 2006, 155, 387-389.	3.7	247
60	Twenty-four-Hour Control With Latanoprost-Timolol Fixed Combination Therapy vs Latanoprost Therapy. JAMA Ophthalmology, 2005, 123, 898.	2.4	69
61	Combination of periocular myocutaneous flaps for one-stage reconstruction of extensive defects of the eyelid. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 2005, 39, 100-103.	0.6	2
62	Endoscopic Placement of Jones Lacrimal Tubes with the Assistance of Holmium YAG Laser. Orbit, 2005, 24, 67-71.	0.8	18
63	Modified Hughes Flap. Ophthalmology, 2005, 112, 2239-2240.	5.2	9
64	Outcome of External Dacryocystorhinostomy Combined With Membranectomy of a Distal Canalicular Obstruction. American Journal of Ophthalmology, 2005, 139, 1051-1055.	3.3	63
65	Endogenous Group G Streptococcus Endophthalmitis following a Dental Procedure. European Journal of Ophthalmology, 2004, 14, 59-60.	1.3	20
66	Wegener's granulomatosis of the orbit in a 5-year-old child. Eye, 2004, 18, 658-660.	2.1	11
67	Nasolacrimal intubation with mitomycin C. Ophthalmology, 2004, 111, 416-417.	5.2	3
68	Tissue plasminogen activator in the management of anterior chamber fibrin formation. Journal of Cataract and Refractive Surgery, 2004, 30, 2254-2255.	1.5	5
69	Low-Dose Tissue Plasminogen Activator. Journal of Cataract and Refractive Surgery, 2003, 29, 2258-2259.	1.5	0
70	Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation. Journal of Cataract and Refractive Surgery, 2003, 29, 729-732.	1.5	12
71	Interventions for involutional lower lid entropion. , 2002, , CD002221.		3
72	Intraobserver and interobserver reliability of the R/D score for evaluation of iris configuration by ultrasound biomicroscopy, in patients with pigment dispersion syndrome. Eye, 2002, 16, 722-726.	2.1	3

#	ARTICLE	IF	CITATIONS
73	Repeatability and reproducibility of upper eyelid measurements. British Journal of Ophthalmology, 2001, 85, 99-101.	3.9	69
74	A comparative study of two procedures for repair of involutional lower lid entropion. Ophthalmology, 2000, 107, 959-961.	5.2	61